Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma

This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.

Inclusion Criteria:

• Fully understand the study and voluntarily sign the informed consent form.
• 18-75 years of age;
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
• Life expectancy ≥ 12 weeks.

Exclusion Criteria:

• Patients were deemed unsuitable for participating in the study by the investigator for any reasons.